Market Overview

The Pullback In Sanofi Is A Buying Opportunity, Says Argus

The Pullback In Sanofi Is A Buying Opportunity, Says Argus
Related SNY
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
European advisory group backs Sanofi's fexinidazole for sleeping sickness (Seeking Alpha)

Argus said in a note released Friday that the recent weakness in Sanofi SA (ADR) (NYSE: SNY) shares offers a buying opportunity. The firm noted that the company's shares fell 2.1 percent over the second quarter compared to a 1-percent increase in the MSCI EAFE Index.

The firm has a Buy rating on Sanofi and a $55 price target.


Argus noted that the company is being plagued by patent expirations on two of its top-selling drugs, namely Lantus for diabetes and Plavix for the prevention of blood clot.

Additionally, the firm said the company is facing legal challenges on its cholesterol lowering drug Praluent, which it is co-developing with Regeneron Pharmaceuticals Inc (NASDAQ: REGN), with Amgen, Inc. (NASDAQ: AMGN) claiming that the drug infringed on patents held by it.

Offsetting Factors

Despite the floundering stock price, analyst John Eade believes the company is beginning to benefit from strong demand for its multiple sclerosis drugs as well as from cost-cutting programs.

"The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.

See also: Where Does Zika Virus Vaccine Research Stand Now?

FY18 Expectations

Argus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.

The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives.


"In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," the firm added.

On technicals, Argus noted that the company's shares are in a bullish pattern, making higher highs and higher lows since October 2016. The firm said the shares are trading at 14 times its 2018 earnings per ADS forecast, which is at the low end of the 14-26 range for large-cap pharma companies.


Image Credit: By Trounce (Own work) [CC BY-SA 2.5 (], via Wikimedia Commons

Latest Ratings for SNY

Nov 2018ArgusMaintainsBuyBuy
Nov 2018BarclaysUpgradesUnderweightEqual-Weight
Sep 2018Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for SNY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Reiteration Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (AMGN + REGN)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Nutanix Hits Its Stride In Q4, But Is The Stock Fully Valued Now?

5 Biggest Price Target Changes For Friday